Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acalabrutinib + Pembrolizumab in Advanced HNSCC
NCT02454179Phase 2Completed
- Sponsor
- Acerta Pharma
- Start
- May 2015
- Primary completion
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of acalabrutinib in head and neck squamous cell carcinoma (HNSCC), sponsored by Acerta Pharma. Started May 2015; status: completed.
02
Drugs
acalabrutinib
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT02454179.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02454179.